Series B AI companies in London

Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people. Every day, and with each new breakthrough, we’re getting closer to achieving our ambitious mission to one day solve all disease

• Series B
• 424 employees
• Founded 2021

hVIVO plc (Ticker: HVO) is a science‐led early‐phase drug development company purpose‐built to meet the growing complexity of modern clinical research. The Company operates an integrated early‐phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‐ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.With industry‐leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‐growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‐built human challenge units in the world, complemented by additional early‐phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‐of‐concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.

• Series B
• 243 employees
• Founded 1989

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

• Series B
• 113 employees
• Founded 2019

Orbital Industries is an AI industrial company building physical products - designed with its frontier AI, from the atoms up. By co-designing advanced materials and hardware, the company builds critical infrastructure faster than previously possible. For more information, visit www.orbitalindustries.com

• Series B
• 64 employees
• Founded 2022

Purespring, a clinical-stage precision nephrology company, is pioneering podocyte-targeted, genetically-driven therapies where unmet need is greatest. Our proprietary, category defining GlomTheraTM platform enables local administration of lower dose genetic therapies directly to the podocyte – a specialised kidney cell implicated in a majority of glomerular disease – with the potential for durable treatment effects. We’re developing a multi-asset pipeline focused on both monogenic and non-monogenic renal indications affecting large and underserved patient populations, including lead programmes:• PS-003: Advancing toward clinical development for Alport Syndrome, a rare inherited kidney disease with no approved targeted therapies, with the goal of addressing the underlying genetic cause and potentially modifying disease progression• PS-002: Has entered Phase 1/2 clinical studies for IgA nephropathy (IgAN), aiming to deliver durable efficacy with an improved safety profileSince launching in 2020, Purespring has raised £115 million ($150 million) and is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion and the British Business Bank.

• Series B
• 58 employees
• Founded 2020